A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Competitive inhibition occurs when an inhibitor molecule competes with substrate for the enzyme's active site, increasing the apparent Km while leaving Vmax unchanged. The inhibitor and substrate are mutually exclusive—raising substrate concentration can overcome inhibition. Competitive inhibitors are often structural analogs of the substrate and can be reversible (weak binding) or irreversible (covalent modification).
Use Lineweaver-Burk plots to distinguish competitive from other inhibition types: competitive inhibition shows parallel lines with the same y-intercept (1/Vmax) but different x-intercepts. Study classic examples like statins inhibiting HMG-CoA reductase or ACE inhibitors blocking the angiotensin-converting enzyme.
From Michaelis-Menten kinetics you know that an enzyme binds substrate at its active site to form an enzyme-substrate complex, and that the relationship between substrate concentration and reaction velocity is described by two parameters: Km (the substrate concentration at half-maximal velocity) and Vmax (the maximum velocity when all enzyme is saturated). Competitive inhibition is what happens when a molecule other than the substrate can also fit into that same active site — and when it does, it blocks the substrate from binding.
Think of it like a parking garage with one entrance. The substrate is trying to pull in, but a competitive inhibitor — a molecule that looks enough like the substrate to fit into the same spot — sometimes gets there first. While the inhibitor occupies the active site, no substrate can bind and no product is formed. Crucially, the inhibitor does not damage the enzyme or change its shape; it simply sits in the way. This is why the inhibition is reversible: if substrate concentration rises high enough, substrate molecules will outcompete the inhibitor for access to the active site through sheer numbers.
This competition has a precise kinetic signature. Because the inhibitor and substrate compete for the same site, the enzyme effectively needs more substrate to reach half-maximal velocity — the apparent Km increases. However, if you add enough substrate to fully saturate the enzyme, every active site will eventually be occupied by substrate rather than inhibitor, so the maximum velocity remains the same — Vmax is unchanged. On a Lineweaver-Burk double-reciprocal plot (1/V vs 1/[S]), this appears as lines that converge at the same y-intercept (same 1/Vmax) but have different x-intercepts (different -1/Km). This is the diagnostic fingerprint that distinguishes competitive inhibition from other types.
Many important drugs exploit competitive inhibition. Statins, for example, are structural analogs of HMG-CoA that compete for the active site of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Because the inhibitor resembles the natural substrate, it binds the active site effectively — but because it is not the real substrate, no catalytic reaction occurs. The clinical implication follows directly from the kinetics: competitive inhibitors are most effective when the natural substrate concentration is low, and their effect can be overcome if substrate levels rise. This is why understanding the Km shift matters — it tells you exactly how the dose-response relationship between inhibitor and substrate will play out in a living system.